Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma

ESMO 2024

13 - 17 Sep 2024

Published: 16 Sep 2024

Views: 36

Rating:

Save

Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada

Dr Elimova talks to ecancer at ESMO 2024 about data she presented from an ongoing phase 2 trial looking at zanidatamab plus chemotherapy for the first-line treatment of HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA).

The data suggest that the regimen continues to show promising antitumor activity with encouraging overall survival and a manageable safety profile as a first-line therapy for mGEA.

Related Videos

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Immunotherapy resistance pathways investigated to tailor combination NSCLC...

Prof Pascale Tomasini - Aix-Marseille University, Marseille, France

Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy ( Prof Pascale Tomasini - Aix-Marseille University, Marseille, France )

ESMO 2024: Latest in bladder cancer - expert review

Dr Patrizia Giannatemp, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van...

ESMO 2024: Latest in bladder cancer - expert review ( Dr Patrizia Giannatemp, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van Der Heijden )

Mutational-based treatment approach may significantly improve outcomes in...

Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy

Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours ( Dr Andrea Botticelli - Sapienza Università di Roma, Rome, Italy )

Immunotherapy significantly increases the number of patients free from bowel...

Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK

Immunotherapy significantly increases the number of patients free from bowel cancer ( Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK )

Avelumab combined with regorafenib shows improved outcome in solid tumours with...

Prof Antoine Italiano - Institute Bergonié, Bordeaux, France

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures ( Prof Antoine Italiano - Institute Bergonié, Bordeaux, France )

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru

Targeting BRAF V600E in metastatic colorectal cancer: where are we today? ( Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru )

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy...

Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )

More from ecancer